



# Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy Males

Ute Burkard<sup>1</sup> · Michael Desch<sup>1</sup> · Yury Shatillo<sup>2</sup> · Glen Wunderlich<sup>3</sup> · Salome Rebecca Mack<sup>1</sup> · Christina Schlecker<sup>2</sup> · Aaron M. Teitelbaum<sup>3</sup> · Pingrong Liu<sup>3</sup> · Tom S. Chan<sup>3</sup>

Published online: 14 March 2022  
© The Author(s) 2022

**Correction to: Clinical Drug Investigation (2022) 42:87–99**  
<https://doi.org/10.1007/s40261-021-01111-9>

The article The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy Males, written by Ute Burkard · Michael Desch, Yury Shatillo, Glen Wunderlich, Salome Rebecca Mack, Christina Schlecker, Aaron M. Teitelbaum, Pingrong Liu and Tom S. Chan, was originally published Online First without Open Access. After publication in volume 42, issue 1, page 87–99 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2022 and This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other

third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40261-021-01111-9>.

✉ Ute Burkard  
[ute.burkard@boehringer-ingenelheim.com](mailto:ute.burkard@boehringer-ingenelheim.com)

<sup>1</sup> Boehringer Ingelheim Pharma GmbH & Co. KG,  
Biberach an der Riss, Germany

<sup>2</sup> Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,  
Germany

<sup>3</sup> Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT,  
USA